(Audio player not working? Head to our Soundcloud page to listen to all our podcasts.)
Today on Eden Exchanges we spoke to Craig Cochran who is the Co-Founder and Managing Director of Medcan Group Pty Ltd (“ Medcan,”, “the Company”) a business dedicated to providing reliable access to patient specific medicinal cannabis products, working with BlueMount Capital. Listen as Craig highlights the barriers of operation in Australia, the change of legislation and how Medcan aims to be the No. 1 supplier of pharmaceutical grade medical cannabis in Australia.
Previous experience in the industry and Craig’s current role
- What is Medcan?
Craig describes Medcan and its mission
Why Medcan is a unique model and the number one provider in Australia
- Regulation and legalisation
Australia’s legalisation of Medicinal cannabis and the regulations Medcan has overcome to exist today
- The product
The impact of medicinal cannabis products compared to alternative and traditional options and where you can find Medcan
- Research and studies
The known prejudice towards using cannabis for medicinal purposes and research and studies that suggest positive outcomes for patients
- The major markets
How the demand for medicinal cannabis fairs around the world and Medcan’s prospects for partnership and growth opportunity
- Strategic priorities
Where Medcan’s focus lies at present and the milestones to overcome in 2020
- Board members and support
The main supporters of Medcan and its mission to provide quality grade pharmaceutical cannabis to everyone in need
- Drives and motivation
What drives Craig to continue with Medcan in a controversial industry and to continue to grow the business
- Be a part of Medcan’s mission
How to get involved with the business
- How to get in touch
How to contact Craig or a member of the team from BlueMount Capital
About the business
Founded with a single vision to provide Australian patients with a high quality, fair priced product, Medcan Australia is positioned to be a front runner in the Australia Medicinal Cannabis Industry.
With a vertically integrated model Medcan Australia will Cultivate, Produce and Manufacture high quality medicinal cannabis products for both clinical trials and individual patient access. Our automated cultivation processes are designed to ensure consistent results so consumers are assured the quality, composition and reliability of their supply.
Medcan Australia was granted the 13th Cultivation and Production licence from the Office of Drug Control in November 2017 with a nominated commencement start date for production being the 1st of July 2018. Medcan was also granted the ODC Medical Cannabis Manufacture Licence. The Company recently announced the successful sale of 90% of its first shipment of imported Medcan Australia branded products into the Australian market.
Medcan Australia believes Medicinal Cannabis is not simply a “one pill suits all” solution. Individual patients have specific needs and requirements and we aim to provide a specific product range based on a patient’s specific set of circumstances.
DISCLAIMER: Eden Exchange Pty Ltd and BlueMount Capital (QLD) Pty Ltd have taken all reasonable care in publishing the information contained in this Director Briefing Podcast. It is information given in a summary form and does not purport to be complete. The information contained is not intended to be used as the basis for making any investment decision and you are solely responsible for any use you choose to make of the information. We strongly advise that you seek independent professional advice before making any investment decisions. Eden Exchange Pty Ltd and BlueMount Capital Pty Ltd are not responsible for any consequences of the use you make of the information, including any loss or damage you or a third party might suffer as a result of that use.
For previous Director Briefings or to receive future Director Briefings and Podcasts, visit Eden Exchange’s Director Briefing Service or phone +613 8658 2292.